15/02/2019 12:35:00

Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit — New Research Emphasizes Economic Growth

NEW YORK, Feb. 15, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of BCE, Inc. (NYSE:BCE), Nektar Therapeutics (NASDAQ:NKTR), Hormel Foods Corporation (NYSE:HRL), Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), MongoDB, Inc. (NASDAQ:MDB), and Regal Beloit Corporation (NYSE:RBC), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

BCE DOWNLOAD: https://Fundamental-Markets.com/register/?so=BCE

NKTR DOWNLOAD: https://Fundamental-Markets.com/register/?so=NKTR

HRL DOWNLOAD: https://Fundamental-Markets.com/register/?so=HRL

ENTA DOWNLOAD: https://Fundamental-Markets.com/register/?so=ENTA

MDB DOWNLOAD: https://Fundamental-Markets.com/register/?so=MDB

RBC DOWNLOAD: https://Fundamental-Markets.com/register/?so=RBC

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine BCE, Inc. (NYSE:BCE), Nektar Therapeutics (NASDAQ:NKTR), Hormel Foods Corporation (NYSE:HRL), Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), MongoDB, Inc. (NASDAQ:MDB), and Regal Beloit Corporation (NYSE:RBC) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice:

the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed February 13th, 2019. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

BCE, INC. (BCE) REPORT OVERVIEW

BCE's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, BCE reported revenue of $4,498.26MM vs $4,530.48MM (down 0.71%) and analysts estimated basic earnings per share $0.69 vs $0.69 (down 0.16%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, BCE reported revenue of $17,525.44MM vs $16,402.19MM (up 6.85%) and analysts estimated basic earnings per share $2.41 vs $2.52 (down 4.30%). Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.63. The estimated EPS forecast for the next fiscal year is $2.79 and is expected to report on February 6th, 2020.

To read the full BCE, Inc. (BCE) report, download it here: https://Fundamental-Markets.com/register/?so=BCE

-----------------------------------------

NEKTAR THERAPEUTICS (NKTR) REPORT OVERVIEW

Nektar Therapeutics' Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Nektar Therapeutics reported revenue of $27.76MM vs $152.93MM (down 81.85%) and analysts estimated basic earnings per share -$0.56 vs $0.39. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Nektar Therapeutics reported revenue of $307.71MM vs $165.44MM (up 86.00%) and analysts estimated basic earnings per share -$0.62 vs -$1.10. Analysts expect earnings to be released on March 7th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was -$0.14. The estimated EPS forecast for the next fiscal year is -$1.49 and is expected to report on March 7th, 2019.

To read the full Nektar Therapeutics (NKTR) report, download it here: https://Fundamental-Markets.com/register/?so=NKTR

-----------------------------------------

HORMEL FOODS CORPORATION (HRL) REPORT OVERVIEW

Hormel Foods' Recent Financial Performance

For the three months ended October 31st, 2018 vs October 31st, 2017, Hormel Foods reported revenue of $2,524.70MM vs $2,492.61MM (up 1.29%) and analysts estimated basic earnings per share $0.49 vs $0.41 (up 19.51%). For the twelve months ended October 31st, 2018 vs October 31st, 2017, Hormel Foods reported revenue of $9,545.70MM vs $9,167.52MM (up 4.13%) and analysts estimated basic earnings per share $1.91 vs $1.60 (up 19.38%). Analysts expect earnings to be released on February 21st, 2019. The report will be for the fiscal period ending January 31st, 2019. Reported EPS for the same quarter last year was $0.44. The estimated EPS forecast for the next fiscal year is $1.98 and is expected to report on November 19th, 2019.

To read the full Hormel Foods Corporation (HRL) report, download it here: https://Fundamental-Markets.com/register/?so=HRL

-----------------------------------------

ENANTA PHARMACEUTICALS, INC. (ENTA) REPORT OVERVIEW

Enanta Pharmaceuticals' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Enanta Pharmaceuticals reported revenue of $69.89MM vs $38.11MM (up 83.38%) and basic earnings per share $1.34 vs $0.61 (up 119.67%). For the twelve months ended September 30th, 2018 vs September 30th, 2017, Enanta Pharmaceuticals reported revenue of $206.63MM vs $102.81MM (up 100.97%) and analysts estimated basic earnings per share $3.74 vs $0.93 (up 302.15%). Analysts expect earnings to be released on May 14th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.61. The estimated EPS forecast for the next fiscal year is -$1.04 and is expected to report on November 25th, 2019.

To read the full Enanta Pharmaceuticals, Inc. (ENTA) report, download it here: https://Fundamental-Markets.com/register/?so=ENTA

-----------------------------------------

MONGODB, INC. (MDB) REPORT OVERVIEW

MongoDB's Recent Financial Performance

For the three months ended October 31st, 2018 vs October 31st, 2017, MongoDB reported revenue of $64.99MM vs $41.49MM (up 56.64%) and analysts estimated basic earnings per share -$0.59 vs -$1.39. For the twelve months ended January 31st, 2018 vs January 31st, 2017, MongoDB reported revenue of $154.52MM vs $101.36MM (up 52.45%) and analysts estimated basic earnings per share -$4.06 vs -$7.10. Analysts expect earnings to be released on March 12th, 2019. The report will be for the fiscal period ending January 31st, 2019. The reported EPS for the same quarter last year was -$0.40. The estimated EPS forecast for the next fiscal year is -$2.38 and is expected to report on March 12th, 2019.

To read the full MongoDB, Inc. (MDB) report, download it here: https://Fundamental-Markets.com/register/?so=MDB

-----------------------------------------

REGAL BELOIT CORPORATION (RBC) REPORT OVERVIEW

Regal Beloit's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Regal Beloit reported revenue of $925.40MM vs $856.90MM (up 7.99%) and analysts estimated basic earnings per share $1.18 vs $1.40 (down 15.71%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Regal Beloit reported revenue of $3,360.30MM vs $3,224.50MM (up 4.21%) and analysts estimated basic earnings per share $4.78 vs $4.55 (up 5.05%). Analysts expect earnings to be released on May 6th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $1.34. The estimated EPS forecast for the next fiscal year is $6.90 and is expected to report on February 3rd, 2020.

To read the full Regal Beloit Corporation (RBC) report, download it here: https://Fundamental-Markets.com/register/?so=RBC

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:

Andrew Duffie, Media Department

Office: +1 667-401-0010

E-mail: media@Fundamental-Markets.com

© 2019 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Related content
10 Apr - 
Market Trends Toward New Normal in Tesla, Zuora, SunOpt..
10 Apr - 
New Research: Key Drivers of Growth for Weatherford Int..
10 Apr - 
Investor Expectations to Drive Momentum within Diamond ..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Multiplying Good Recognizes Local Volunteers for Outstanding Public Service at 2019 Jefferson Awards in Washington, D.C.
2
Green Plains Prices Offering of $105 Million Aggregate Principal Amount of 4.00% Convertible Senior Notes due 2024
3
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Indivior, Heron Therapeutics, Mammoth Energy, and ChinaCache and Encourages Investors to Contact the Firm
4
CLASS ACTION REMINDERS for FND, LTHM, PSMT, and AOS: Hagens Berman Reminds Investors of Class Actions on Behalf of Shareholders
5
CLASS ACTION REMINDERS for CLDR, TUSK and RMED: Hagens Berman Reminds Investors of Class Actions on Behalf of Shareholders

Related stock quotes

Hormel Foods Corporation 40.51 -0.9% Stock price decreasing
Nektar Therapeutics 35,61 1.3% Stock price increasing
Enanta Pharmaceuticals I.. 90.90 0.0% Stock price decreasing
Regal Beloit Corporation 79.87 0.1% Stock price increasing
BCE Inc 45.26 0.5% Stock price increasing

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
19 June 2019 18:47:55
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB7 - 2019-06-19 19:47:55 - 2019-06-19 18:47:55 - 1000 - Website: OKAY